CASI Pharmaceuticals Inc.

2.96-0.1300-4.21%Vol 120.40K1Y Perf 98.08%
Jun 24th, 2022 16:00 DELAYED
BID2.95 ASK3.04
Open3.10 Previous Close3.09
Pre-Market- After-Market2.99
 - -  0.03 1.01%
Target Price
4.50 
Analyst Rating
Strong Buy 1.00
Potential %
52.03 
Finscreener Ranking
★★★★★     59.43
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★★★+     54.28
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★+     41.25
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
0.06 
Earnings Rating
Sell
Market Cap40.27M 
Earnings Date
12th May 2022
Alpha0.00 Standard Deviation0.25
Beta0.67 

Today's Price Range

2.953.17

52W Range

2.87174.00

5 Year PE Ratio Range

-15.20-6.90

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-0.67%
1 Month
534.65%
3 Months
248.11%
6 Months
240.23%
1 Year
98.08%
3 Years
-1.00%
5 Years
190.20%
10 Years
61.75%

TickerPriceChg.Chg.%
CASI2.96-0.1300-4.21
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
3.40
3.80
0.01
0.03
165.00
Leverage Ratio 1.60
ProfitabilityValueIndustryS&P 500US Markets
58.10
-97.00
-91.80
-
-91.23
RevenueValueIndustryS&P 500US Markets
33.49M
2.46
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.10-0.0640.00
Q04 2021-0.06-0.0433.33
Q03 2021-0.06-0.07-16.67
Q02 2021-0.09-0.0544.44
Q01 2021-0.05-0.11-120.00
Q04 2020-0.07-0.12-71.43
Q03 2020-0.06-0.14-133.33
Q02 2020-0.08-0.0712.50
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.06-20.00Negative
9/2022 QR-0.0516.67Positive
12/2022 FY-0.228.33Positive
12/2023 FY-0.16-700.00Negative
Next Report Date-
Estimated EPS Next Report-0.10
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume120.40K
Shares Outstanding13.61K
Shares Float11.05M
Trades Count654
Dollar Volume360.51K
Avg. Volume340.44K
Avg. Weekly Volume97.00K
Avg. Monthly Volume533.73K
Avg. Quarterly Volume390.58K

CASI Pharmaceuticals Inc. (NASDAQ: CASI) stock closed at 2.96 per share at the end of the most recent trading day (a -4.21% change compared to the prior day closing price) with a volume of 120.40K shares and market capitalization of 40.27M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 125 people. CASI Pharmaceuticals Inc. CEO is Wei-Wu He.

The one-year performance of CASI Pharmaceuticals Inc. stock is 98.08%, while year-to-date (YTD) performance is 270%. CASI stock has a five-year performance of 190.2%. Its 52-week range is between 2.865 and 174, which gives CASI stock a 52-week price range ratio of 0.06%

CASI Pharmaceuticals Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 0.54, a price-to-sale (PS) ratio of 1.21, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -22.59%, a ROC of -35.21% and a ROE of -35.84%. The company’s profit margin is -91.23%, its EBITDA margin is -91.80%, and its revenue ttm is $33.49 Million , which makes it $2.46 revenue per share.

Of the last four earnings reports from CASI Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.10 for the next earnings report. CASI Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for CASI Pharmaceuticals Inc. is Strong Buy (1), with a target price of $4.5, which is +52.03% compared to the current price. The earnings rating for CASI Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CASI Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CASI Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 17.65, ATR14 : 0.27, CCI20 : 29.35, Chaikin Money Flow : -0.40, MACD : 0.57, Money Flow Index : 40.35, ROC : -11.90, RSI : 64.93, STOCH (14,3) : 15.70, STOCH RSI : 0.00, UO : 40.38, Williams %R : -84.30), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CASI Pharmaceuticals Inc. in the last 12-months were: Wei-Wu He (Buy at a value of $2 288 106)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
3 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.

CEO: Wei-Wu He

Telephone: +1 240 864-2600

Address: 9620 Medical Center Drive, Rockville 20850, MD, US

Number of employees: 125

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

63%37%

Bearish Bullish

53%47%

TipRanks News for CASI

News

Stocktwits